Filing Flows › TG Therapeutics (TGTX) › How it makes money
How TG Therapeutics (TGTX) makes money
TG Therapeutics (TGTX) made $240M of revenue in the second quarter 2026 (Q2 2026), +70% from a year earlier. Product brought in $236M (98%); License brought in $4.5M (2%). Of every dollar of revenue, 9¢ was left as operating profit, 3¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q2 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Product | $236M | 98.1% | +17% | +70% |
| License | $4.5M | 1.9% | +26% | +97% |
Where each dollar of revenue goes
| Line | Q2 2026 | % of revenue |
|---|---|---|
| Revenue | $240M | 100.0% |
| Operating profit | $21.7M | 9.0% |
| Income tax | $2.5M | 1.0% |
| Net earnings | $7.8M | 3.2% |
| Operating cash flow | $39.3M | 16.3% |
| Free cash flow | $39.0M | 16.2% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q2 2026 | $240M | +70% |
| Q1 2026 | $205M | +70% |
| Q4 2025 | $193M | +78% |
| Q3 2025 | $162M | +93% |
| Q2 2025 | $141M | +92% |
| Q1 2025 | $121M | +90% |
| Q4 2024 | $108M | +146% |
From TG Therapeutics' 10-Q filed Aug 5, 2026 (on EDGAR).
Questions
How does TG Therapeutics make money?
TG Therapeutics (TGTX) made $240M of revenue in the second quarter 2026 (Q2 2026), +70% from a year earlier. Product brought in $236M (98%); License brought in $4.5M (2%). Of every dollar of revenue, 9¢ was left as operating profit, 3¢ was left as net earnings.
What is TG Therapeutics' biggest business?
Product: $236M in the second quarter 2026, 98% of revenue, +70% from a year earlier.
What is TG Therapeutics' profit margin?
Net earnings were $7.8M, 3.2% of revenue, in the second quarter 2026; the operating margin was 9.0%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.